Literature DB >> 11344193

Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity.

F Callies1, M Fassnacht, J C van Vlijmen, I Koehler, D Huebler, M J Seibel, W Arlt, B Allolio.   

Abstract

Studies in animals and humans using supraphysiological doses of dehydroepiandrosterone (DHEA) reported significant changes in body composition and carbohydrate metabolism. To investigate the metabolic action of a physiological DHEA replacement dose, we studied 24 women with adrenal insufficiency (AI; mean +/- SD age, 42.3 +/- 9.3 yr; duration of disease, 9.2 +/- 8.4 yr; body mass index, 23.4 +/- 4.0 kg/m(2)) in a double blind, placebo-controlled, randomized, cross-over design. They received 50 mg DHEA/day and placebo orally for 4 months each, with a 1 -month washout period. Measurements included fasting serum glucose, insulin, leptin, bone markers, anthropometric parameters determined by bioimpedance analysis, and exercise capacity as assessed by an incremental cycling test. DHEA did not induce any change in body mass index (placebo vs. DHEA, 23.3 +/- 4.1 vs. 23.2 +/- 3.9 kg/m(2); P = 0.39), parameters of body composition, or exercise capacity. However, compared with placebo, DHEA replacement led to a significant decrease in serum leptin (absolute change after 4 months, DHEA vs. placebo, -5.3 +/- 8.0 vs. 1.1 +/- 5.7 ng/mL; P = 0.01). This is most likely the result of the DHEA-induced normalization of circulating androgens. DHEA had no effect on fasting glucose, insulin, or the glucose/insulin ratio. Compared with placebo, serum osteocalcin increased slightly, but significantly, during DHEA treatment (absolute change after 4 months DHEA vs. placebo, +1.6 +/- 5.3 vs. -1.2 +/- 6.2 ng/mL; P = 0.02). However, urinary cross-links excretion did not change. In conclusion, replacement of DHEA in a physiological dose in patients with pathological DHEA deficiency does not have a significant effect on carbohydrate metabolism, body composition, or exercise capacity. The biological relevance of the changes in leptin and osteocalcin levels remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344193     DOI: 10.1210/jcem.86.5.7483

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Adrenal insufficiency.

Authors:  Stefanie Hahner; Richard J Ross; Wiebke Arlt; Irina Bancos; Stephanie Burger-Stritt; David J Torpy; Eystein S Husebye; Marcus Quinkler
Journal:  Nat Rev Dis Primers       Date:  2021-03-11       Impact factor: 52.329

2.  Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.

Authors:  R Libè; L Barbetta; C Dall'Asta; F Salvaggio; C Gala; P Beck-Peccoz; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

Review 3.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses.

Authors:  S Laureti; A Falorni; F Santeusanio
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

5.  Determinants of serum leptin levels in healthy postmenopausal women.

Authors:  I Lambrinoudaki; G Christodoulakos; C Panoulis; D Botsis; D Rizos; A Augoulea; G Creatsas
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

Review 6.  [Replacement therapy with adrenal steroids].

Authors:  S Hahner; B Allolio
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

7.  Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen.

Authors:  Heng-hui Cheng; Xiao-jing Hu; Qiu-rong Ruan
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

Review 8.  A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?

Authors:  Nikolaos Samaras; Dimitrios Samaras; Emilia Frangos; Alexandre Forster; Jacques Philippe
Journal:  Rejuvenation Res       Date:  2013-08       Impact factor: 4.663

9.  Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial.

Authors:  D von Mühlen; G A Laughlin; D Kritz-Silverstein; J Bergstrom; R Bettencourt
Journal:  Osteoporos Int       Date:  2007-12-15       Impact factor: 4.507

10.  Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial.

Authors:  Thomas P Walsh; Grayson L Baird; Michael K Atalay; Saurabh Agarwal; Daniel Arcuri; James R Klinger; Christopher J Mullin; Heather Morreo; Brynn Normandin; Sruti Shiva; Mary Whittenhall; Corey E Ventetuolo
Journal:  Pulm Circ       Date:  2021-05-21       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.